Novartis COX-189 TARGET Study Will Assess CV Safety Of COX-2 Inhibitor

Novartis' long-term COX-2 inhibitor safety study will be sufficiently large to provide "clear" evidence of the cardiovascular safety of COX-189, Clinical R&D Head James Shannon told analysts in New York City Oct. 30